Chargement en cours...
Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa
INTRODUCTION: The rapid clearance of factor IX necessitates frequent intravenous administrations to achieve effective prophylaxis for patients with hemophilia B. Subcutaneous administration has historically been limited by low bioavailability and potency. Dalcinonacog alfa was developed using a rati...
Enregistré dans:
| Publié dans: | PLoS One |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Public Library of Science
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7592742/ https://ncbi.nlm.nih.gov/pubmed/33112889 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0240896 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|